Legato Capital Management LLC Buys Shares of 6,479 Janux Therapeutics, Inc. (NASDAQ:JANX)

Legato Capital Management LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,479 shares of the company’s stock, valued at approximately $347,000.

A number of other hedge funds also recently added to or reduced their stakes in JANX. Plato Investment Management Ltd raised its stake in shares of Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Avanza Fonder AB bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at about $139,000. AQR Capital Management LLC bought a new stake in shares of Janux Therapeutics during the second quarter valued at about $215,000. Finally, Chicago Capital LLC bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at about $230,000. 75.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus lifted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partners lifted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $89.90.

Insider Activity

In related news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the completion of the sale, the chief executive officer now owns 257,054 shares of the company’s stock, valued at approximately $13,263,986.40. The trade was a 8.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,668 shares of company stock worth $4,872,515 in the last 90 days. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Trading Down 2.2 %

NASDAQ JANX opened at $36.37 on Friday. The company has a market cap of $1.91 billion, a PE ratio of -31.09 and a beta of 3.16. Janux Therapeutics, Inc. has a 1 year low of $8.28 and a 1 year high of $71.71. The stock’s 50-day moving average price is $48.79 and its two-hundred day moving average price is $48.03.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.